Nutricircle Limited has announced a board meeting scheduled for February 13, 2026, to deliberate on key financial and corporate matters. The meeting represents a significant milestone for the company as it prepares to review its quarterly performance and execute strategic capital structure decisions.

Meeting Details and Agenda

The board meeting will convene at 3:00 p.m. at the company's registered office located at Ayesha Residency, Public Garden Road, Nampally, Hyderabad. The comprehensive agenda encompasses critical financial and corporate governance matters that require board approval.

Financial Results Review

The primary agenda item involves consideration and approval of the unaudited standalone financial results for the quarter and nine months ended December 31, 2025. This quarterly review will provide stakeholders with insights into the company's operational performance during the third quarter of fiscal year 2026. The board will also review the limited review report accompanying these financial statements, ensuring compliance with regulatory requirements.

Warrant Conversion Initiative

A significant corporate action on the agenda involves the allotment and conversion of convertible warrants into equity shares. The conversion parameters demonstrate the company's commitment to strengthening its capital base through strategic equity infusion.

Regulatory Compliance and Approvals

The warrant conversion process has received necessary regulatory clearances, including shareholder approval through a special resolution passed during the extraordinary general meeting held on September 24, 2024. BSE Limited granted in-principle approval on December 2, 2024, facilitating the execution of this corporate action. The company operates under CIN L18100TG1993PLC015901 and maintains BSE code 530219.

Corporate Governance Framework

The meeting notification, issued on February 10, 2026, demonstrates adherence to SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 29(1) and 33. Managing Director HPitesh Mohanalal Patel, holding DIN 02080625, signed the official communication, ensuring proper corporate governance protocols are maintained throughout the process.

Nutricircle Limited has launched its Next-Generation Plant Proteins at Gulfood Dubai 2026, marking a significant milestone in the company's expansion into international markets. The launch took place on January 26, 2026, at the APEDA Pavilion, Dubai Exhibition Centre, during the world's largest annual food and beverage trade exhibition.

Product Innovation and Technology

The company's breakthrough innovation centers on harnessing the power of Indian agriculture to address India's and the world's growing protein and nutrition challenges through a consumer health-first, science-led approach. Nutricircle is redefining how nutrition is produced and consumed by unlocking the potential of indigenous millets, pulses, and rice, building an integrated value chain based on its core philosophy of Soil-Seeds-Science-Sustainability-Solutions.

Revolutionary Millet-Based Proteins

Nutricircle has established itself as the first company to isolate protein from indigenous millets such as foxtail millet, amaranth, and pearl millet, alongside high-protein chickpea, horse gram, lentils, and other native super grains. The company's portfolio includes protein concentrates and isolates ranging from 28% to 95%, depending on the source crop, designed as functional ingredients for multiple industries.

The target industries for these innovative protein solutions include:

• Food & Beverages
• Nutraceuticals & Sports Nutrition
• Pharmaceuticals
• Bakery
• Snacks
• Functional Foods

High-Protein Chickpea Innovation

A key highlight of Nutricircle's innovation pipeline is its high-protein chickpea, developed in collaboration with the International Crops Research Institute for the Semi-Arid Tropics (ICRISAT). This unique chickpea variety contains up to 28% protein and yields a functional protein rich in albumins and globulins, offering excellent solubility, emulsification, foaming, and gelling properties.

The bioactive peptides in this innovative chickpea variety support cardiovascular and immune health, while prebiotic fibres enhance gut health, making it ideal for meat analogues, dairy alternatives, flours, pastas, and protein-fortified foods.

Regulatory Compliance

The announcement was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to transparent corporate governance and regulatory compliance. The disclosure was signed by Managing Director Hitesh Mohan Patel and filed with BSE Limited under BSE Code 530219.